Utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogs
Abstract Background Dogs with chronic enteropathies (CE) displayed elevated IgA seropositivity against specific markers that can be used to develop a novel test. Objective To assess a multivariate test to aid diagnosis of CE in dogs and to monitor treatment‐related responses. Animals One hundred fif...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-05-01
|
Series: | Journal of Veterinary Internal Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1111/jvim.16132 |
id |
doaj-86ccc436c8df4ca19c5ad1cc2bb5d837 |
---|---|
record_format |
Article |
spelling |
doaj-86ccc436c8df4ca19c5ad1cc2bb5d8372021-07-14T06:50:33ZengWileyJournal of Veterinary Internal Medicine0891-66401939-16762021-05-013531306131510.1111/jvim.16132Utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogsJuan Estruch0Jacqueline Johnson1Sarah Ford2Sean Yoshimoto3Tracy Mills4Philip Bergman5Vetica Labs, Inc. San Diego California USACabrillo Pet Hospital San Diego California USADepartment of Internal Medicine Blue Pearl Specialty Scottsdale Arizona USADepartment of Internal Medicine West LA Animal Hospital Los Angeles California USADepartment of Clinical Studies West LA Animal Hospital Los Angeles California USADepartment of Internal Medicine Katonah Bedford Veterinary Center New York New York USAAbstract Background Dogs with chronic enteropathies (CE) displayed elevated IgA seropositivity against specific markers that can be used to develop a novel test. Objective To assess a multivariate test to aid diagnosis of CE in dogs and to monitor treatment‐related responses. Animals One hundred fifty‐seven dogs with CE/inflammatory bowel disease (IBD), 24 dogs non‐IBD gastrointestinal disorders, and 33 normal dogs. Methods Prospective, multicenter, clinical study that enrolled dogs with gastrointestinal disorders. Serum sample collected at enrollment and up to 3 months follow‐up measuring OmpC (ACA), canine calprotectin (ACNA), and gliadin‐derived peptides (AGA) by ELISA. Results Seropositivity was higher in CE/IBD than normal dogs (66% vs 9% for ACA; 55% vs 15% for ACNA; and 75% vs 6% for AGA; P < .001). When comparing CE/IBD with non‐IBD disease, ACA and ACNA displayed discriminating properties (66%, 55% vs 12.5%, 29% respectively) while AGA separated CE from normal cohorts (54% vs 6%). A 3‐marker algorithm at cutoff of ACA > 15, ACNA > 6, AGA > 60 differentiates CE/IBD and normal dogs with 90% sensitivity and 96% specificity; and CE/IBD and non‐IBD dogs with 80% sensitivity and 86% specificity. Titers decreased after treatment (47%‐99% in ACA, 13%‐88% in ACNA, and 30%‐85% in AGA), changes that were concurrent with clinical improvements. Conclusion and Clinical Importance An assay based on combined measurements of ACA, ACNA, and AGA is useful as a noninvasive diagnostic test to distinguish dogs with CE/IBD. The test also has the potential to monitor response to treatment.https://doi.org/10.1111/jvim.16132calprotectinCE/IBDGI monitoringgliadinsOmpC |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Juan Estruch Jacqueline Johnson Sarah Ford Sean Yoshimoto Tracy Mills Philip Bergman |
spellingShingle |
Juan Estruch Jacqueline Johnson Sarah Ford Sean Yoshimoto Tracy Mills Philip Bergman Utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogs Journal of Veterinary Internal Medicine calprotectin CE/IBD GI monitoring gliadins OmpC |
author_facet |
Juan Estruch Jacqueline Johnson Sarah Ford Sean Yoshimoto Tracy Mills Philip Bergman |
author_sort |
Juan Estruch |
title |
Utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogs |
title_short |
Utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogs |
title_full |
Utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogs |
title_fullStr |
Utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogs |
title_full_unstemmed |
Utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogs |
title_sort |
utility of the combined use of 3 serologic markers in the diagnosis and monitoring of chronic enteropathies in dogs |
publisher |
Wiley |
series |
Journal of Veterinary Internal Medicine |
issn |
0891-6640 1939-1676 |
publishDate |
2021-05-01 |
description |
Abstract Background Dogs with chronic enteropathies (CE) displayed elevated IgA seropositivity against specific markers that can be used to develop a novel test. Objective To assess a multivariate test to aid diagnosis of CE in dogs and to monitor treatment‐related responses. Animals One hundred fifty‐seven dogs with CE/inflammatory bowel disease (IBD), 24 dogs non‐IBD gastrointestinal disorders, and 33 normal dogs. Methods Prospective, multicenter, clinical study that enrolled dogs with gastrointestinal disorders. Serum sample collected at enrollment and up to 3 months follow‐up measuring OmpC (ACA), canine calprotectin (ACNA), and gliadin‐derived peptides (AGA) by ELISA. Results Seropositivity was higher in CE/IBD than normal dogs (66% vs 9% for ACA; 55% vs 15% for ACNA; and 75% vs 6% for AGA; P < .001). When comparing CE/IBD with non‐IBD disease, ACA and ACNA displayed discriminating properties (66%, 55% vs 12.5%, 29% respectively) while AGA separated CE from normal cohorts (54% vs 6%). A 3‐marker algorithm at cutoff of ACA > 15, ACNA > 6, AGA > 60 differentiates CE/IBD and normal dogs with 90% sensitivity and 96% specificity; and CE/IBD and non‐IBD dogs with 80% sensitivity and 86% specificity. Titers decreased after treatment (47%‐99% in ACA, 13%‐88% in ACNA, and 30%‐85% in AGA), changes that were concurrent with clinical improvements. Conclusion and Clinical Importance An assay based on combined measurements of ACA, ACNA, and AGA is useful as a noninvasive diagnostic test to distinguish dogs with CE/IBD. The test also has the potential to monitor response to treatment. |
topic |
calprotectin CE/IBD GI monitoring gliadins OmpC |
url |
https://doi.org/10.1111/jvim.16132 |
work_keys_str_mv |
AT juanestruch utilityofthecombineduseof3serologicmarkersinthediagnosisandmonitoringofchronicenteropathiesindogs AT jacquelinejohnson utilityofthecombineduseof3serologicmarkersinthediagnosisandmonitoringofchronicenteropathiesindogs AT sarahford utilityofthecombineduseof3serologicmarkersinthediagnosisandmonitoringofchronicenteropathiesindogs AT seanyoshimoto utilityofthecombineduseof3serologicmarkersinthediagnosisandmonitoringofchronicenteropathiesindogs AT tracymills utilityofthecombineduseof3serologicmarkersinthediagnosisandmonitoringofchronicenteropathiesindogs AT philipbergman utilityofthecombineduseof3serologicmarkersinthediagnosisandmonitoringofchronicenteropathiesindogs |
_version_ |
1721303942301745152 |